HIV‐1 viral load determination based on reverse transcriptase activity recovered from human plasma

We describe a procedure (ExaVir™ Load) to carry out human immunodeficiency virus‐1 (HIV‐1) viral load testing using reverse transcriptase (RT) recovered from HIV‐1 virions in plasma. Samples from individuals infected with HIV‐1 were treated with a sulphydryl‐reactive agent to inactivate endogenous polymerases. Virions were then immobilised on a gel and washed in individual mini columns to remove RT‐inhibiting antibodies, antiviral drugs, and other RT inhibitors. Immobilised virions were lysed finally, and the viral RT eluted. The amount of RT recovered was quantified by a sensitive RT activity assay using either colorimetry or fluorimetry to detect DNA produced by RT. The “RT load” values of 390 samples from 302 HIV‐1 patients living in Sweden were compared to results obtained with an HIV‐1 RNA viral load assay. The correlation between the two tests was r = 0.90, P < 0.0001. Four of 202 samples from healthy blood donors gave low positive values in the RT test. All samples in a panel with 10 HIV‐1 subtypes were positive by the RT load. The RT load test provides a technically less demanding and cost‐effective alternative to methods based on nucleic acid amplification. Being insensitive to genetic drift occurring in HIV, the assay should be of particular use in resource‐limited settings, where different subtypes and recombinant HIV strains occur. J. Med. Virol. 71:347–359, 2003. © 2003 Wiley‐Liss, Inc.

[1]  A. Sönnerborg,et al.  Use of HIV-1 reverse transcriptase recovered from human plasma for phenotypic drug susceptibility testing , 2003, AIDS.

[2]  J. Braun,et al.  A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes , 2003, AIDS.

[3]  G. Ippolito,et al.  Underevaluation of HIV-1 plasma viral load by a commercially available assay in a cluster of patients infected with HIV-1 A/G circulating recombinant form (CRF02). , 2002, Journal of acquired immune deficiency syndromes.

[4]  S. Sigurdsson,et al.  Structural basis for the inhibitory efficacy of efavirenz (DMP-266), MSC194 and PNU142721 towards the HIV-1 RT K103N mutant. , 2002, European journal of biochemistry.

[5]  Y. Schmitt Performance characteristics of quantification assays for human immunodeficiency virus type 1 RNA. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[6]  L. Jagodzinski,et al.  Use of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 To Assess the Performance of Viral RNA Quantitation Tests , 2000, Journal of Clinical Microbiology.

[7]  D. Podzamczer,et al.  Efavirenz associated with corticosteroids in patients with previous severe hypersensitivity reaction due to nevirapine. , 2000, AIDS.

[8]  P. Vernazza,et al.  Performance of five different assays for the quantification of viral load in persons infected with various subtypes of HIV-1. Swiss HIV Cohort Study. , 2000 .

[9]  P. Vernazza,et al.  Performance of Five Different Assays for the Quantification of Viral Load in Persons Infected With Various Subtypes of HIV‐1 , 2000, Journal of acquired immune deficiency syndromes.

[10]  W. Heneine,et al.  Quantitation of Human Immunodeficiency Virus Type 1 Group O Load in Plasma by Measuring Reverse Transcriptase Activity , 2000, Journal of Clinical Microbiology.

[11]  J. Böni,et al.  Prospective evaluation of amplification-boosted ELISA for heat-denatured p24 antigen for diagnosis and monitoring of pediatric human immunodeficiency virus type 1 infection. , 1999, The Journal of infectious diseases.

[12]  J. Mascola,et al.  Development of Calibrated Viral Load Standards for Group M Subtypes of Human Immunodeficiency Virus Type 1 and Performance of an Improved AMPLICOR HIV-1 MONITOR Test with Isolates of Diverse Subtypes , 1999, Journal of Clinical Microbiology.

[13]  F. Gao,et al.  Detection of Phylogenetically Diverse Human Immunodeficiency Virus Type 1 Groups M and O from Plasma by Using Highly Sensitive and Specific Generic Primers , 1999, Journal of Clinical Microbiology.

[14]  M. Bendinelli,et al.  A colorimetric reverse transcriptase assay optimized for Moloney murine leukemia virus, and its use for characterization of reverse transcriptases of unknown identity. , 1998, Journal of virological methods.

[15]  W. Heneine,et al.  Measurement of human immunodeficiency virus type 1 plasma virus load based on reverse transcriptase (RT) activity: evidence of variabilities in levels of virion-associated RT. , 1998, The Journal of infectious diseases.

[16]  E. Fenyö,et al.  Differences in reverse transcriptase activity versus p24 antigen detection in cell culture, when comparing a homogeneous group of HIV type 1 subtype B viruses with a heterogeneous group of divergent strains. , 1998, AIDS research and human retroviruses.

[17]  J. Albert,et al.  Subtype‐specific problems with quantification of plasma HIV‐1 RNA , 1997, AIDS.

[18]  R. Thorstensson,et al.  Measurement of levels of human immunodeficiency virus type 1 reverse transcriptase (RT) and RT activity-blocking antibody in human serum by a new standardized colorimetric assay , 1997, Journal of clinical microbiology.

[19]  Robert W. Coombs,et al.  Longitudinal Analysis of Quantitative Virologic Measures in Human Immunodeficiency Virus-Infected Subjects with ⩾400 CD4 Lymphocytes: Implications for Applying Measurements to Individual Patients , 1997 .

[20]  T. Leitner,et al.  Most HIV‐1 genetic subtypes have entered Sweden , 1997, AIDS.

[21]  M. Fischl,et al.  Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection , 1997, Antimicrobial agents and chemotherapy.

[22]  M. Peeters,et al.  Comparative evaluation of three assays for the quantitation of human immunodeficiency virus type 1 RNA in plasma , 1996, Journal of medical virology.

[23]  J. Gronowitz,et al.  A sensitive assay for the quantification of reverse transcriptase activity based on the use of carrier‐bound template and non‐radioactive‐product detection, with special reference to human‐immunodeficiency‐virus isolation , 1996, Biotechnology and applied biochemistry.

[24]  M. Bendinelli,et al.  The feline lymphoid cell line MBM and its use for feline immunodeficiency virus isolation and quantitation. , 1995, Veterinary immunology and immunopathology.

[25]  D. van Strijp,et al.  Distinct changes in HIV type 1 RNA versus p24 antigen levels in serum during short-term zidovudine therapy in asymptomatic individuals with and without progression to AIDS. , 1995, AIDS research and human retroviruses.

[26]  M Pistello,et al.  Feline immunodeficiency virus: an interesting model for AIDS studies and an important cat pathogen , 1995, Clinical microbiology reviews.

[27]  E A Emini,et al.  Susceptibilities of human immunodeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reserve transcriptase inhibitors , 1994, Antimicrobial Agents and Chemotherapy.

[28]  M. Pistello,et al.  Detection of feline immunodeficiency virus in saliva and plasma by cultivation and polymerase chain reaction , 1993, Journal of clinical microbiology.

[29]  S. Hughes,et al.  The effects of cysteine mutations on the reverse transcriptases of human immunodeficiency virus types 1 and 2. , 1992, The Journal of biological chemistry.

[30]  J. Lennerstrand,et al.  HIV reverse transcriptase inhibiting antibodies detected by a new technique: Relation to p24 and gp41 antibodies, HIV antigenemia and clinical variables , 1991, Journal of medical virology.

[31]  F. Grosse,et al.  Fidelity of human immunodeficiency virus type I reverse transcriptase in copying natural DNA. , 1989, Nucleic acids research.